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Mutations in leucine-rich repeat kinase 2 (LRRK2), such as G2019S, are associated with an 
LQFUHDVHG ULVN RI GHYHORSLQJ 3DUNLQVRQ¶V GLVHDVH A CHK1-derived LRRK2 G2019S kinase 
domain surrogate was obtained and validated by comparing its affinity with LRRK2 inhibitors 
and their LRRK2 G2019S activity. X-ray crystal structures of the surrogate with known LRRK2 
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inhibitors rationalized their potency and selectivity. Fragment hit-derived arylpyrrolo[2,3-b]-
pyridine LRRK2 inhibitors underwent surrogate structure-guided optimization. LRRK2-pSer935 
HEK293 IC50 for 22 on LRRK2 WT and its G2019S and A2016T mutants was 24 nM, 40 nM 
and 471 nM, respectively. Cellular data for 22 were consistent with binding to Ala2016 in 
LRRK2 (equivalent to Ala147 in CHK1 10-pt. mut. structure). 22 was shown to be potent, 
selective, orally available and brain-penetrant in wild-type mice, and confirmation of target 
engagement was demonstrated, with LRRK2-pSer935 IC50 values for 22 in mouse brain and 
kidney being 1.3 nM and 5 nM, respectively. 
 
INTRODUCTION 
3DUNLQVRQ¶V GLVHDVH (PD) is a neurodegenerative disorder typically characterized by motor 
symptoms of resting tremor, slowness of movement and muscular rigidity, as well as non-motor 
symptoms such as pain and depression.1 Pathologically, the disease is identified by the loss of 
dopaminergic neurons, with a consequent decrease in dopamine levels in the brain and by 
aggregation of the protein Į-synuclein in the dopaminergic neurons. These aggregations, known 
as Lewy bodies, are composed of insoluble Į-synuclein, associated with other proteins such as 
ubiquitin.2 Current PD therapies aim at increasing the dopamine levels in areas innervated by 
dopaminergic neurons in the brain; none, however, address the underlying disease-causing 
problem. Many alternative approaches to treating PD are therefore under investigation,3,4 one of 
which is inhibition of leucine-rich repeat kinase 2 (LRRK2). 
LRRK2 is a 2527 amino acid, multi-domain protein involved in catalyzing phosphorylation 
and GTP-GDP hydrolysis.5,6,7,8 Evidence showing a relationship between LRRK2 and the 
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pathogenesis of PD is mounting.9,10 It has been shown that LRRK2 phosphorylates Į-synuclein 
at Ser129, and this phosphorylated form constitutes a significant part of Lewy bodies.11 
Additionally, single nucleotide polymorphisms in the functional domains of LRRK2 have been 
associated with familial DQGVSRUDGLF3DUNLQVRQ¶VGLVHDVH12 Importantly, the clinical features of 
PD associated with LRRK2 mutations cannot be distinguished from those featuring in idiopathic 
PD.13 This strongly suggests a common pathogenic mechanism, and that LRRK2 activity is a 
rate-limiting factor in PD progression.14  
Several LRRK2 pathogenic variants have been identified in PD patients,15 most commonly the 
G2019S substitution in the activation loop of the kinase domain of the protein.16 G2019S PD is 
inherited in an autosomal dominant fashion, suggesting a gain-of-function mutation of the 
LRRK2 protein.17 In support of this hypothesis, biochemical studies on G2019S, as well as 
I2020T mutants, showed increased kinase activity of LRRK2.18 This suggests a causal 
involvement of overactive LRRK2 in the pathogenesis of familial forms of PD. Thus, inhibitors 
of LRRK2, including the G2019S mutation, could be used as disease modifying treatment in 
familial PD.19,20,21,22,23,24,25,26,27,28,29,30  
LRRK2 kinase domain inhibitors previously reported (Figure 1) range from broad spectrum 
kinase inhibitors such as staurosporine 1,31 to more selective inhibitors such as aminopyrimido-
benzodiazepinone 2 (LRRK2-IN-1),32 which have poor CNS penetration. Further efforts have led 
to the discovery of CNS penetrant, selective inhibitors such as arylbenzamide 3a 
(GSK2578215A),33 aminopyrimidine 4a (GNE-7915),34 pyrrolopyrimidines 5 (PF-06447475)35 
and 6 (JH-II-127),36 indazole 7 (MLi-2),37,38 and aminopyridine 8.39 There has not yet, however, 
been a report on the progression of a compound into the clinic, which would require sufficient 
target engagement, and an acceptable pharmacokinetic and safety profile.40,41 
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The design of LRRK2 inhibitors has been impeded in part by the complexity of this large 
multi-domain protein, such that stable, soluble, crystallizable kinase domain constructs have not 
yet been obtained.42 Discovery efforts have primarily used homology models based on other 
kinases with similar sequence identity in the ATP binding site of LRRK2, such as ALK,43,44 B-
Raf,45,46,47,48 ERK2,38 JAK2,34,49,50,51 IRAK4,52 Lck,53 MLK1,39,54,55 ROCK156,33 or TAK1,57,58  or 
analysis of ligand-bound X-ray crystal structures with off-target kinases such as TTK,34 MST335 
or Tyk259 to rationalize selectivity. Roco4, a LRRK2 homolog from amoeba, has been used to 
approximate some aspects of the human LRRK2 ATP binding site.60 More recently, ligand 
bound crystal structures of selective LRRK2 inhibitors in complex with a humanized form of 
Roco4 have been described, in which two point mutations give the surrogate increased 
resemblance to LRRK2.61 We report herein the design of a LRRK2 surrogate obtained from the 
introduction of 10 point mutations into checkpoint kinase 1 (CHK1 10-pt. mut.), its validation by 
comparing the binding affinity of LRRK2 inhibitors with the mutant protein and their LRRK2 
G2019S activity, solving X-ray crystal structures of the protein in complex with known literature 
inhibitors of LRRK2 and comparing these with existing models to rationalize selectivity, and its 
use in the optimization of a series of arylpyrrolo[2,3-b]-pyridine inhibitors. 
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Figure 1. Representative set of reported LRRK2 inhibitors 1±8. 
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RESULTS AND DISCUSSION 
An analysis of the RCSB protein data bank (PDB)62 identified ten protein kinase structures 
with >50% ATP binding site similarity to LRRK2. These included mixed-lineage kinase 
(MLK1), the crystal structure 3DTC63 of which has formed the basis of LRRK2 homology 
models previously reported.39,55,54 CHK1 was selected as a start point, however, guided by 
previous in-house experience of the expression, purification and crystallization of CHK1 
constructs to enable ligand-bound X-ray crystal structures, and their utility in the design of novel 
inhibitors of this kinase for the treatment of cancer.64,65 An initial selection of ten residues in 
CHK1 to be mutated (Figure 2) was based on their <4 Å proximity to 1 in the published ligand 
bound X-ray structure with CHK1, 1NVR (Figure 3A).66,67 These residues form key areas of the 
ATP binding site of the kinase domain, which encompass the hinge, gatekeeper and activation 
loop. Importantly, the list of mutations also includes areas known for kinase selectivity. Two 
further constructs, an 8 and 12-pt. mutant of CHK1, were also considered. The latter contained 
two additional mutations in the flexible glycine-rich loop of the ATP binding site (Ser19 and 
Phe20, equivalent to Ser1889 and Phe1890 in LRRK2). The 8-pt. mutant was identical to the 10-
pt. mutant, but did not bear the F149Y mutation in the activation loop of CHK1 (equivalent to 
Tyr2018 in LRRK2), nor did it have the G150S mutation (equivalent to the G2019S mutation in 
LRRK2). Equivalent residues in Roco460 and the humanized Roco4,61 which have been 
previously reported as LRRK2 surrogates, are also shown in Figure 2. 
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Figure 2. Comparison of selected LRRK2 WT and G2019S mutant ATP binding site residues, 
with equivalents in CHK1 WT, and 8, 10 and 12-pt. mutants, as well as Roco4 WT60 and 
humanized Roco4.61 Mutations highlighted in red. 
The CHK1 10-pt. mut. was investigated as a potential LRRK2 kinase domain surrogate in the 
first instance, and was successfully expressed in insect cells infected with baculovirus, purified 
and then crystallized. Following the soak of a protein crystal with 1, X-ray data were collected 
and a crystal structure of the resulting protein-ligand complex was obtained (Figure 3B). 
Reassuringly, binding of the amide moiety of 1 to the hinge via the backbone of Leu86 and 
Glu85 (equivalent to Leu1949 and Glu1948 in LRRK2, and Tyr86 and Glu85 in CHK1) was 
similar to that seen in CHK1 structure, 1NVR. $FU\VWDOVWUXFWXUHRIȖ-imino-ATP in complex 
with CHK1 10-pt. mut. was also obtained, and interactions with the ATP binding site were as 
expected (structure not shown, but deposited in the PDB). 
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Figure 3(A). X-ray structure of 1 (green)/ CHK1 (cyan) (PDB: 1NVR). (B) X-ray structure of 1 
(green)/ CHK1 10-pt. mut. (cyan). Ten residues mutated from CHK1 highlighted in magenta. 
Key intermolecular contacts are shown as dashed lines (polar ligand to backbone contacts <3.3 Å 
in blue; polar ligand to sidechain contacts <3.3 Å in green). 
With the new LRRK2 kinase domain surrogate in hand, its further usefulness was investigated 
by soaking selective LRRK2 inhibitors with apo CHK1 10-pt. mut crystals, and obtaining ligand-
bound X-ray crystal structures. A structure of 2 with CHK1 10-pt. mut. was obtained (Figure 4A) 
and compared with the published crystal structure of the same compound in complex with 
humanized Roco4 kinase (4YZM, Figure 4B).61 Hydrogen bonds between the backbone carbonyl 
and NH of Ala87 in the hinge and the aminopyrimidine moiety of 2 are equivalent to those seen 
between Val1108 and the same ligand in the humanized Roco4 structure. Similarly, the phenyl 
moiety of the tricyclic core is accommodated by the adenine binding pocket of CHK1 10-pt. 
mut., and makes contact with Ala147 (equivalent to Ala2016 in LRRK2), which is 3.6 Å away. 
The other side of the ring is partly covered by the hinge, with the methoxy substituent 3.9 Å 
away from Leu86 (equivalent to Leu1949 in LRRK2). This interaction is significant for kinase 
selectivity, since analysis has shown68 that 40% of kinases have a more sterically encumbered 
B A 
 9 
Tyr and 18% have a Phe in the position equivalent to 1949 (as shown in Figure 3A with CHK1), 
whereas 25% of kinases have Leu. In both structures, the electron density of the (4-
methylpiperazin-1-yl)piperidinyl moiety is weak, since it is solvent exposed and likely very 
flexible. A difference in the glycine loop placement was observed between the two structures, 
however. CHK1 10-pt. mut. incorporates Tyr20, whereas humanized Roco4 has Phe1037, 
identical to Phe1890 in LRRK2. Tyr20 of CHK1 10-pt. mut. makes a polar interaction with the 
carbonyl group of 2 and Lys38 of the salt bridge (Lys1906 in LRRK2) is more distant. In 
contrast, the equivalent Lys1055 in the humanized Roco4 structure makes a polar contact with 
the same carbonyl group of the ligand.  
To address the sequence differences in the glycine rich loop, a crystal structure of 2 in complex 
with a CHK1 12-pt. mutant was also obtained (Figure 4C), in which Ser19 and Phe20 
(equivalent to Ser1889 and Phe1890 in LRRK2) were present. The glycine loop also remained in 
the open position in this structure, and Lys38 (Lys1906 in LRRK2) remained in the same 
position. It is considered that the flexibility of the glycine loop would enable its adjustment to the 
bound ligand, regardless of whether residue 20 is Tyr or Phe, and should not be over-interpreted 
in the structures of complexes with surrogate kinases. 
A crystal structure of 2 in complex with a CHK1 8-pt. mutant was also obtained (Figure 4D), 
identical to the 10-pt. mutant, but without the F149Y and G150S mutations. This was in 
agreement with the structure obtained with the 10 and 12-point mutants, other than the placement 
of the flexible (4-methylpiperazin-1-yl)piperidinyl solubilizer. All three structures of the CHK1 
mutant complexes with 2 reveal they are good models for LRRK2, as residue 19, 20 and 147 
mutations do not play a significant role in the binding of this ligand. 
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Figure 4. (A) X-ray structure of 2 (green)/ CHK1 10-pt. mut. (cyan). Ten residues mutated from 
CHK1 highlighted in magenta. (B) X-ray structure of 2 (green)/ humanized Roco4 kinase 
(cyan).61 Two residues mutated from Roco4 kinase highlighted in magenta. Residues different to 
CHK1 12-pt. mut. and LRRK2 G2019S are highlighted in yellow. (C) X-ray structure of 2 
(green)/ CHK1 12-pt. mut. (cyan). Twelve residues mutated from CHK1 highlighted in magenta. 
(D) X-ray structure of 2 (green)/ CHK1 8-pt. mut. (cyan). Eight residues mutated from CHK1 
highlighted in magenta. Key intermolecular contacts are shown as dashed lines (polar ligand to 
backbone contacts <3.3 Å in blue; polar ligand to sidechain contacts <3.3 Å in green). 
An X-ray crystal structure of 3a33 in complex with CHK1 10-pt. mut. was attempted, to further 
explore the utility of CHK1 mutants as crystallographic surrogates for LRRK2. Due to the low 
A B 
C D 
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solubility of the ligand, and its immediate crystallization in the soaking solution, only partial 
occupancy of 3a in the binding site was observed, with the quality of electron density maps and 
resulting model below accepted standards. Pleasingly, however, a structure of the analogous 
arylbenzamide 3b69,70 in complex with CHK1 10-pt. mut. (Figure 5) was obtained. The ligand 
adopted a conformation which accommodates an intramolecular hydrogen bond between the 
arylbenzamide NH and the ether oxygen atom, and is sandwiched between Leu15 of the glycine 
loop and Leu137, already present in CHK1, and equivalent to Leu1949 and Leu2001 in LRRK2. 
The crystal structure also showed a polar ligand to backbone interaction between the amide 
carbonyl of the ligand and mutated Ala87 in the hinge (equivalent to Ala1950 in LRRK2), as 
well as a hydrophobic contact between the 3-pyridyl moiety of 3b, Ile68 and gatekeeper Met84 
(equivalent to Ile1933 and Met1947 in LRRK2). The N-methylpiperazinyl moiety occupies a 
space next to Leu86 (Ser1951 and Leu1949 in LRRK2), known to impart selectivity for LRRK2 
over other kinases with a Phe or Tyr at this position. 
The binding mode of 3b in CHK1 10-pt. mut. is consistent with that reported for 3a in a 
LRRK2 homology model based on ROCK1,33,56 in which the ligand avoids steric clash with 
Ala2106 in LRRK2 (Ala147 in CHK1 10-pt. mut., 4.2 Å from the pyridyl moiety of the ligand). 
Two further X-ray crystal structures of 3b in complex with the CHK1 8- and 12-pt. mutants 
were also obtained (not shown, but structures deposited in the PDB), and these structures were 
highly analogous to that obtained with CHK1 10-pt. mut. Based on the three structures of the 
CHK1 mutant complexes with 3b, as well as structures of complexes with 2, we concluded that 
the CHK1 10-pt. mut. is a good representation of a LRRK2 kinase domain surrogate, and that 
protein was then used for all further structure determinations. 
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Figure 5. X-ray structure of 3b (green) in complex with CHK1 10-pt. mut. (cyan). Residues 
mutated from CHK1 highlighted in magenta. Key polar contacts <3.3 Å in blue dashed lines. 
A crystal structure of 4a in complex with CHK1 10-pt. mut. was also obtained (Figure 6a), and 
compared with the published structure of analogous 4b34 bound to humanized Roco4 (Figure 
6b).61 The hinge binding aminopyrimidine moiety of 4a forms characteristic hydrogen bonds 
with the backbone carbonyl and NH of Ala87 in CHK1 10-pt. mut. (Ala1950 in LRRK2), which 
are equivalent to those seen between 4b and Val1108 in the humanized Roco4 structure. The 
trifluoromethyl substituent of 4a forms multiple hydrophobic contacts with Val23 of the glycine 
loop, Ile68, Met84 gatekeeper, Leu137 and Ala147 of the activation loop, which are comparable 
with interactions between the same moiety of 4b and Val1040, Val1091, Met1105, Leu1161 and 
Ala1176 in the humanized Roco4 structure. The trifluoromethyl group of 4a makes a water 
mediated contact with Glu55 (Glu1920 in LRRK2) of the Į-helix, in a similar fashion to that of 
4b and Glu1078 of Roco4. A water mediated contact between the ligand and Asp148 (Asp2017 
in LRRK2) of the activation loop is not observed, as is seen with the equivalent Asp1177 in the 
Roco4 structure, since Asp148 makes a hydrogen bond contact with Ser150, equivalent to 
Ser2019 in the LRRK2 G2019S mutant. Additionally, a water mediated contact is observed 
between the fluoro substituent of 4a and Ser91 in the hinge (equivalent to Ser1954 in LRRK2). 
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This residue remains as Asp1112 in the Roco4 structure. The methoxy group of 4a occupies 
space in the roof of the hinge created by the backbone of Ser88 and residue of Leu86, equivalent 
to Pro1109 (which confers additional rigidity on the protein backbone in comparison with 
LRRK2) and Leu1107 in the Roco4 structure. The morpholino moiety of 4a has some electron 
density; this part is solvent exposed, and not recognized specifically by the kinase domain. 
 
Figure 6. X-ray structure of (A) 4a (green) in complex with CHK1 10-pt. mut. (cyan), and (B) 
4b (green) in complex with humanized Roco4 kinase (cyan).61 Mutated residues are highlighted 
in magenta. Residues different to CHK1 10-pt. mut. and LRRK2 G2019S in humanized Roco4 
are highlighted in yellow. Polar intermolecular contacts <3.3 Å are shown as dashed lines. 
Similar relationships between LRRK2 selectivity and binding mode in the surrogate were 
observed in other inhibitor chemotypes disclosed more recently. Indazole 7 bears a 1-
methylcyclopropoxy substituent, the methyl group of which is placed 4 Å from Ala147 in the 
CHK1 10-pt. mut. crystal structure (Ala1950 in LRRK2), whilst the cyclopropyl moiety is 
enclosed by the glycine-rich loop, including hydrophobic interaction with Val23 (Val1893). The 
2,6-dimethylmorpholinyl moiety occupies the space next to Leu86, analogous to Leu1949 in 
A B 
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LRRK2. These interactions are in agreement with those observed un an ERK2-dervived 
homology model.38 Aminopyridine 839 adopts a conformation in which one methyl group of its 
isopropyl substituent is 4.2 Å away from Ala147 and C6 of the pyridine ring sits 3.7 Å from 
Leu86; it is likely that both hydrophobic contacts increase selectivity for LRRK2. 
 
 
Figure 7. X-ray structures of (A) indazole 7 and (B) 2-aminopyridine 8 (green) in complex with 
CHK1 10-pt. mut. (cyan). Mutated residues are highlighted in magenta. Polar intermolecular 
contacts <3.3 Å are shown as dashed lines. 
The LRRK2 G2019S activity of 41 LRRK2 inhibitors previously described in the literature, 
including 2-aminopyridines,39 and also pyrrolopyridines disclosed herein was determined, and 
compared with binding affinity for CHK1 10-pt. mut. in a LanthaScreen europium binding assay 
(Figure 8). Correlation coefficient (r2) was 0.57 and Spearman's rho rank correlation coefficient 
was 0.77, showing a reasonable statistical dependence between the two variables. In contrast, 
there was no correlation between LRRK2 G2019S activity and CHK1 binding affinity (see 
supporting information), thus providing further evidence for the utility of the CHK1 10-pt. 
mutant as a LRRK2 surrogate. 
A B 
 15 
 
Figure 8. Plot of p(LRRK2 G2019S Lanthascreen activity cKi) vs p(CHK1 10-pt mut. binding 
affinity cKi) for 41 LRRK2 inhibitors. 
Pyrrolopyrimidines35,36,71 and pyrrolopyridines72 have been under investigation as LRRK2 
inhibitors by a number of groups. A crystal structure of highly potent and brain penetrant 5 in 
complex with CHK1 10-pt. mut. was obtained (Figure 9A). Binding of the ligand to the hinge via 
the backbone of Ala87 and Glu85 (equivalent to Ala1950 and Glu1948 in LRRK2) was 
observed, and the bicyclic core is positioned 3.6 Å from Leu86 (Leu1949 in LRRK2) in the roof 
of the hinge. The nitrile group makes a weak hydrogen bond to Lys38 (3.7 Å), and a water 
PHGLDWHGFRQWDFWZLWK*OXRIWKHĮ-helix. These data are in good overall agreement with the 
published structure of 5 in complex with MST3 (PDB code 4U8Z),35 however MST3 does not 
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bear the Y101L mutation, equivalent to Leu86 in CHK1 10-pt. mut, and Leu1949 in LRRK2, 
which may enable binding of more selective ligands. 
A crystal structure of CHK1 10-pt. mut. and 6, reported as high potent, selective and brain 
penetrant LRRK2 inhibitor,36 was also obtained (Figure 9B). Key ligand-protein interactions 
were in line with a reported docking study based on Roco4 kinase, which predicted three 
hydrogen bonds from the pyrrolopyrimidine to the hinge via Leu1949 and Ala1950. 
Additionally, docking suggested the possibility of a halogen interaction with the gatekeeper 
Met1947 and the 5-chloro substituent of the ligand. The equivalent interactions with Leu86, 
Ala87 and Met84 in CHK1 10-pt. mut. were observed. In addition, the 5-chloro substituent 
makes a water mediated interaction with the salt bridge comprised of Lys38 and Asp148, as well 
as Glu55. The methoxy group sits between the Leu86 residue and Ser88 backbone in the hinge 
extension, and the amide carbonyl sits out-of-plane, making a water-mediated contact with 
Asp94, so that the morpholine substituent tucks under the glycine loop. Asp94 is equivalent to 
Arg1957 in LRRK2, His1115 in Roco4 and Asp109 in MST3; there is therefore potential in 
LRRK2 for a direct contact between Arg1957 and the amide carbonyl, which is not observed in 
these surrogates. 
 
Figure 9. X-ray crystal structures of pyrrolopyrimidines (A) 5 and (B) 6, and (C) pyrrolopyridine 
9 (green) in complex with CHK1 10-pt. mut. (cyan). Residues mutated from CHK1 highlighted 
A B C 
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in magenta. Key polar contacts <3.3 Å indicated with blue dashed lines. Likely water-mediated 
hydrogen bonds indicated in yellow dashed lines. 
The present authors identified pyrrolopyridine 973 [LRRK2 G2019S IC50 415 nM, cKi 27 nM,
74 
ligand efficiency (LE)75 0.58] in a biochemical screen of an in-house library focused on low 
molecular weight compounds with known kinase hinge binding motifs (Table 1). This was a 
representative of fragment hit 1H-pyrrolo[2,3-b]pyridine (48% @ 200 µM, estimated Ki 15 µM, 
LE 0.74) which arose from a fragment library screen which was also conducted using the same 
biochemical assay format. An X-ray crystal structure of 9 in complex with CHK1 10-pt. mut. 
was obtained (Figure 9C). Binding of 9 to the hinge via the backbone of Ala87 and Glu85 
(equivalent to Ala1950 and Glu1948 in LRRK2) was observed, and the bicyclic core is 
positioned 3.9 Å from Leu86 (Leu1949 in LRRK2) in the roof of the hinge. The nitrile moiety 
sits close to the Met84 gatekeeper (Met1947 in LRRK2), and picks up water mediated 
interactions with the salt bridge comprised of Asp148 and Lys38, as well as a water mediated 
FRQWDFWZLWK *OXRI WKHĮ-helix. Subsequent screening of fragments 1076,73 (cKi ~3 µM, LE 
0.68) and 1173 (cKi ~2 µM, LE 0.65) indicated that a significant binding efficiency arose from 
the polar interactions in the hinge and water mediated contact with the salt bridge via the nitrile. 
The phenol substituent of 9, positioned between the flexible Gly loop, Ala147 and Asp148, 
underwent initial optimization. The corresponding phenyl and thiophen-3-yl analogues 12 and 
13
76 had activities within three-fold of the start point 9. Chloro or methyl substitution of the 
phenyl ring of 9 (14±19) indicated that the meta-substituted examples 15 and 18 were better 
tolerated than ortho or para.  This was further confirmed by 3-methoxy derivative 20 (cKi 24 
nM). 6-Amino substitution of the pyrrolopyridine core of 12 was carried out, with a view to 
enhancing interaction with the hinge region of the ATP binding site of the kinase. This gave rise 
 18 
to 21 (cKi 12 nM), which was seven-fold more potent on LRRK2. A similar uplift in potency was 
observed with the 6-amino derivative of 18; 22 had a LRRK2 G2019S cKi of 2 nM, whilst 
maintaining a high LE of 0.62. LRRK2 WT activities of compounds were in agreement with 
those determined on LRRK2 G2019S, and these data are also presented in Table 1. 
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Table 1. LRRK2 G2019S and WT Lanthascreen activity of pyrrolo[2,3-b]pyridines 9±22. 
 
Compd R
1
 R
2
 
LRRK2 Lanthascreen activity 
G2019S WT 
IC50 
(nM)
a
 
cKi  
(nM) 
LE 
IC50 
(nM)
b
 
cKi  
(nM) 
LE 
9 H 3-Hydroxyphenyl 415 27 0.58 487 13 0.60 
10 ³ H 46522 2702 0.68 101080 3026 0.66 
11 ³ Cl 37765 2193 0.65 n.d.   
12 ³ Phenyl 1178 81 0.57 954 23 0.62 
13 ³ Thiophen-3-yl 870 60 0.61 1279 31 0.65 
14 ³ 2-Chlorophenyl 9271 538 0.47 7531 225 0.49 
15 ³ 3-Chlorophenyl 1275 81 0.54 784 23 0.59 
16 ³ 4-Chlorophenyl 1983 136 0.50 n.d.   
17 ³ 2-Methylphenyl 27838 1617 0.44 26163 783 0.47 
 20 
a250 pM protein, 1.3 mM ATP. b1 nM protein, 1.3 mM ATP; n.d., not determined. 
  
18 ³ 3-Methylphenyl 195 13 0.60 170 4 0.64 
19 ³ 4-Methylphenyl 1639 95 0.54 4135 124 0.53 
20 ³ 3-Methoxyphenyl 354 24 0.55 247 6 0.59 
21 NH2 Phenyl 176 12 0.61 140 3 0.65 
22 ³ 3-Methylphenyl 33 2 0.62 21 0.5 0.67 
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An X-ray crystal structure of 22 in complex with CHK1 10-pt. mut. was obtained (Figure 
10A). As also seen with the original hit 9, binding of the ligand to the hinge via the backbone of 
Ala87 and Glu85 (equivalent to Ala1950 and Glu1948 in LRRK2) was observed. The nitrile 
group is also placed next to the Met84 gatekeeper, and links via waters to the salt bridge 
comprised of Lys38, Glu55 and Asp148. The 3-tolyl substituent is bounded by the Gly loop, with 
which it likely makes van der Waals interactions. The methyl group points towards a small 
hydrophobic pocket formed of Ala147 and the stem of Asp148. Ala147, equivalent to Ala2016 in 
LRRK2, is not well conserved across the kinome, and interaction in this region of space likely 
imparts selectivity for LRRK2. 
 
Figure 10. X-ray crystal structures of (A) 22 and (B) 23 (green) in complex with CHK1 10-pt. 
mut. (cyan). Residues mutated from CHK1 highlighted in magenta. Key polar contacts <3.3 Å 
indicated with blue dashed lines. Likely intramolecular and water-mediated hydrogen bonds 
indicated in yellow dashed lines. 
Phosphorylation sites, including Ser935 and Ser1292, have been used as pharmacodynamic 
markers for LRRK2 target engagement in vitro and in vivo.77 Further evidence for the interaction 
A B 
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of 22 with Ala2016 was therefore obtained from in-cell western (ICW) assay-based LRRK2 IC50 
values, which were determined using HEK293 LRRK2-pSer935 assays in either a 96-well 
(transient transfected cells) or a 384-well set-up (BacMam transduced cells). 22 had LRRK2-
pSer935 IC50 values of 24 nM, 40 nM and 471 nM for LRRK2 WT, G2019S and A2016T, 
respectively (Figure 11 and Table 2, 96-well assay). In a 384-well set-up, 22 showed similar 
potencies in ICW LRRK2 G2019S cell-based Ser935 and Ser1292 phosphorylation assays, with 
IC50 values of 70 nM and 61 nM, respectively (Table 2). 
The ~10-fold drop in potency of 22 between LRRK2 WT and G2019S when compared to 
A2016T that is observed in the cell-based assay is in agreement with the crystallographic 
evidence obtained from the CHK1 10-pt mut. that 22, via the methyl group on the tolyl 
substituent, engages with Ala2016 in both human LRRK2 WT and G2019S. 
 
Figure 11. ICW assay data showing inhibition of LRRK2-Ser935 phosphorylation in HEK293 
cells overexpressing LRRK2 WT, and the G2019S and A2016T mutants, by 22. 
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Table 2. Cell-based IC50 values of 22 on LRRK2 WT, G2019S and A2016T. 
 
LRRK2 
variant 
LRRK2-pSer935 
(96-well)
a
 
LRRK2-pSer935 
(384-well)
b
 
LRRK2-pSer1292 
(384-well)
b
 
IC50 
(nM) 
pIC50 IC50  
(nM) 
pIC50 IC50  
(nM) 
pIC50 
WT 24 7.61±0.06  
(n = 3) 
67 7.17±0.20  
(n = 6) 
n.d.  
G2019S 40 7.40±0.01  
(n = 3) 
70 7.16±0.16  
(n = 6) 
61 7.21±0.17  
(n = 3) 
A2016T 471 6.33±0.05  
(n = 3) 
n.d.  n.d.  
aTransient transfection LI-COR ICW assay (HEK293).70 
bBacMAM LI-COR ICW assay (HEK293);  n.d., not determined. 
 
22 had moderate MDCK-MDR1 permeability (Papp A:B 8.6 cm/sec x 10
-6), low efflux ratio 
(B:A/A:B 0.7) and moderate rat and human microsomal clearance (9 and 1.5 L/kg/h, 
respectively). Pharmacokinetic and pharmacodynamic profiling on 22 in wild-type mice was 
performed using LRRK2 phosphorylation at serine 935 as the readout for LRRK2 inhibition 
(Figure 12). Following 25 mg/kg oral dosing of 22 in wild-type mice, full LRRK2 inhibition in 
mouse brain was observed for at least 12 h. The mean unbound drug concentration at 12 h was 
10 ng/g (~40 nM). LRRK2-pSer935 levels were back to 80% 24 h after dosing.   
 24 
 
Figure 12. Pharmacokinetic and pharmacodynamic profile of 22 in mouse brain following 25 
mg/ kg po dosing: (A) exposure of 22 over 24 hours, (B) relative LRRK2-pSer935 levels in 
mouse brain over 24 hours.  
Further in vivo exploration at Cmax in wild-type mice found that LRRK2-pSer935 IC50 values for 
22 in mouse brain and kidney were 1.3 nM and 5 nM, respectively (Figure 13A and B). 
 
 
Figure 13. Dose-response relationship of 22 in mouse brain and kidney: (A) brain studies (n=3), 
(B) mouse kidney studies (n=2). LRRK2-pSer935 levels were assessed one hour after po dosing; 
the data were used to estimate IC50 values for 22. 
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Assessment of the in vitro kinase selectivity of 22 by a DiscoveRx KINOMEscan assay at 1 
µM identified 21 off-target hits with % control <5% (i.e. >95% inhibition), including JAK3, 
Tyk2 and TTK, indicating that further improvement to selectivity would be required. 22 was also 
assessed in cultured human peripheral blood mononuclear cells (PBMCs) using ActivX KiNativ 
technology,78 in order to give further indication of LRRK2 potency and a wider assessment of 
kinase selectivity. 22 gave 91% inhibition on LRRK2 @ 1 µM, with no inhibition of other 
kinases >60% (including JAK3; Tyk2 and TTK were not present in this panel). 22 also 
underwent broad in vitro pharmacology profiling by Eurofins CEREP at 1 µM. Although 22 
showed radioligand binding affinity for adenosine A1, A2A, A3 and 5-HT2B receptors, no 
significant agonist or antagonist effects were observed at doses up to 10 µM in follow-up studies. 
22, however, gave positive results in an Ames bacterial mutagenicity assay and also during 
assessment of compound-induced genomic instability in TK6 cells. Further optimization, with a 
focus on improving potency and kinase selectivity, was therefore required. 
1-Methyl-1H-pyrazol-3-yl substitution on the primary amino group of 22 gave rise to 2376 
which had increased LRRK2 G2019S IC50 8 nM (cKi 0.1 nM) (Table 3). An X-ray crystal 
structure of 23 in complex with CHK1 10-pt. mut. was obtained (Figure 10B), in which the 
ligand forms the same interactions as 22. In addition, 23 adopts a conformation such that the 6-
(1-methyl-1H-pyrazol-3-yl)amino substituent forms an intramolecular hydrogen bond between 
N2 of the pyrazole and the CH of the pyrrolopyridine core. C4 and 5 of the pyrazole ring also 
makes van der Waals contact with Gly90 in the roof of the hinge (Gly1953 in LRRK2), which 
likely explains the increased potency on LRRK2. 
23 also had enhanced activity in the LRRK2 G2019S-pSer935 HEK293 ICW 384-well assay, 
with IC50 18 nM. The aqueous solubility of crystalline material was low (<0.1 µg/ ml), however 
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MDCK-MDR1 permeability was moderate (Papp A:B 8.8 cm/sec x 10
-6), and efflux ratio was low 
(B:A/A:B 0.6). Rat and human microsomal clearance were 6 and 8.5 L/kg/h respectively, 
indicating a disconnect between the two species. Following 10 mg/ kg po dosing of 23 in mouse, 
there was no plasma exposure. A vehicle screen, followed by sc dosing in mouse of 2 mg/kg 
resulted in a maximum brain concentration of 25 ng/g, at time points of 30 min and 1 hour after 
GRVLQJ7KHIUHHEUDLQFRQFHQWUDWLRQZDV§ 0.025 ng/g (corresponding to 0.076 nM, close to the 
LRRK2 G2019S cKi of 0.1 nM). 23 was also assessed in human cultured PBMCs using the 
ActivX KiNativ assay. Encouragingly, 23 gave 83% inhibition @ 100 nM on LRRK2 and 93% 
inhibition @ 1 µM. At 100 nM, there was no inhibition of other kinases, and at 1 µM, there was 
no inhibition of other kinases >50%, other than JAK1 (55%), JAK3 (53%) and JNK1 (71%). 
Modifications to the structure of 23 were carried out, with a view to optimizing its 
physicochemical properties, and thus PK profile, for exposure in the CNS (Table 3). Removal of 
the methyl substituent (24) reduced human microsomal clearance significantly. This also led to a 
reduction in LRRK2 activity of 24, however, likely explained by loss of hydrophobic contact 
between the methyl group and stem of Asp148 and Ala147 in CHK1 10-pt. mut. Replacing R2 
with a range of methylpyridyl substituents was also explored (25±28). This led to a reduction in 
human microsomal clearance in each case; however, the 4-methylpyridin-2yl analogue 25 was 
significantly less active in the LRRK2 kinase assay. It is likely that introduction of a nitrogen 
atom at this position would encourage co-planarity between the bicyclic core of the molecule and 
the pyridyl substituent, thus disrupting hydrophobic contacts with the molecule. Additionally, the 
nitrogen atom would likely be positioned in the vicinity of the conserved Val23 residue of the 
Gly loop, with which it would form an unfavorable interaction. Furthermore, 25±28 had an 
efflux ratio of >2, and therefore unlikely to have the desired CNS exposure in vivo. 
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4-Substitution on the pyrazole ring was well tolerated in the LRRK2 enzyme and cell assays 
(29±31), which is consistent with space being available in the hinge extension adjacent to Leu86, 
as shown in the crystal structure of 23 (Figure 10B). Unfortunately, this modification led to 
increased microsomal clearance and efflux. 4-Chloro substitution on the pyrazole ring was also 
well tolerated in the LRRK2 enzyme and cell assays. In comparison with methyl derivatives 29±
31, 32±34 had lower efflux ratio. This was still in excess of 2, however, and high human 
microsomal clearance rendered compounds from this series unsuitable for further progression. 
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Table 3. LRRK2 G2019S and WT Lanthascreen and cell-based activity, human liver microsomal 
clearance, MDR1-MDCK permeability and efflux ratio of pyrrolo[2,3-b]pyridines 23±34. 
 
Compd R
1
 R
2
 
LRRK2 kinase 
activity 
LRRK2 pSer935 
HEK293 
(384-well) 
HLM  
CL 
(mL/min
/Kg) 
Papp A:B 
(MDCK) 
(cm/sec × 
10
-6
) 
B:A/
A:B G2019S 
IC50 
(nM)
a
 
WT 
IC50 
(nM)
b
 
G2019S 
IC50 
(nM)
c
 
WT 
IC50 
(nM) 
23 H 3-Methylphenyl 8 3 18 17 8.5 8.8 0.6 
24 ³ Phenyl 112 99 100 85 4.5 5.9 0.4 
25 ³ 
4-
Methylpyridin-
2-yl 
324 205 n.d. n.d. 1.3 5.0 4.2 
26 ³ 
5-
Methylpyridin-
3-yl 
37 27 90 70 2.3 2.3 3.6 
27 ³ 
2-
Methylpyridin-
4-yl 
55 102 130 700 2.9 2.5 2.3 
28 ³ 
6-
Methylpyridin-
2-yl 
41 28 160 76 1.0 5.2 4.9 
29 Me 
5-
Methylpyridin-
3-yl 
48 43 170 160 3.8 0.9 17.5 
30 ³ 
2-
Methylpyridin-
4-yl 
108 215 210 580 4.7 1.7 17.0 
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31 ³ 
6-
Methylpyridin-
2-yl 
50 36 170 130 2.1 1.6 27.7 
32 Cl 
5-
Methylpyridin-
3-yl 
68 67 190 93 4.2 3.6 4.2 
33 ³ 
2-
Methylpyridin-
4-yl 
158 180 210 1300 4.8 4.1 4.5 
34 ³ 
6-
Methylpyridin-
2-yl 
57 44 94 110 2.8 2.8 7.9 
a250 pm protein, 1.3 mM ATP. b1 nM protein, 1.3 mM ATP. cn.d., not determined. 
 
CHEMISTRY 
The synthesis of 12±21 is summarized in Scheme 1. Commercially available 11 underwent 
Suzuki cross-coupling with boronic acids to give 12±20 directly. Treatment of 11 with m-CPBA, 
followed by methansesulfonic acid, afforded the N-oxide 35. Subsequent treatment of 35 with 
dimethyl sulfate and then 7N ammonia in methanol afforded 36, which underwent Suzuki cross-
coupling with phenylboronic acids to give 21.  
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Scheme 1. Synthesis of compounds 12±21.a 
 
aReagents and conditions: (a) ArB(OH)2, KF, [(tert-Bu)3P]2Pd(0), 1,4-dioxane, H2O, 150 °C; 
(b) ArB(OH)2, K2CO3, Pd(dppf)Cl2, THF, H2O, 120 °C; (c) m-CPBA, CHCl3, 0° C to rt; (d) 
MeSO3H; (e) Me2SO4, MeCN, 60 °C; (f) 7N NH3/ MeOH, 70 °C; (g) ArB(OH)2, KF, [(tert-
Bu)3P]2Pd(0), 1,4-dioxane, H2O, 120 °C; (h) PhB(OH)2, K2CO3, Pd(dtbpf)Cl2, THF, H2O, 120 
°C. 
The synthesis of 22 is summarized in Scheme 2. Trimethylsilylethoxymethyl (SEM) protection 
of 11 gave 37, which underwent Suzuki coupling to give 38; subsequent SEM deprotection with 
TBAF gave 18. Treatment of 18 with m-CPBA, followed by methansesulfonic acid, afforded the 
N-oxide 39. Reaction of 39 with methanesulfonyl chloride gave intermediate 40, which 
underwent reaction with LHMDS followed by XPhos and 
tris(dibenzylideneacetone)dipalladium(0) to give 22.  
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Scheme 2. Synthesis of compound 22.a 
 
aReagents and conditions: (a) SEMCl, NaH, DMF, 0 °C to rt; (b) 3-MePhB(OH)2, Cs2CO3, 
Pd(PPh3)4, 1,4-dioxane, H2O, 100 °C; (c) TBAF, Et3N, THF, 70 °C; (d) m-CPBA, CH2Cl2, 0° C 
to rt; (e) MeSO3H, rt; (f) MeSO2Cl, DMF, 80 °C; (g) LiHMDS, XPhos, Pd2(dba)3, THF, 60 °C. 
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The synthesis of 23±34 is described in Scheme 3. Reaction of N-oxide intermediate 35 with 
methanesulfonyl chloride gave 4,6-dichloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 41. 
Buchwald-Hartwig amination of 41 with 1-Me-1H-pyrazol-3-amine gave 42 (R1 = H), which 
underwent Suzuki cross-coupling with boronic acids to give 23 or 24 (Method A). The remaining 
analogues 25±34 were prepared by conversion of 41 to the 6-chloro-4-iodo-derivative 43. Where 
R2 = 5-methylpyridin2-yl, 43 underwent Suzuki coupling with a boronic acid and the resulting 
product 44 underwent treatment with SEM chloride to give 45a (Method B). For analogues 
where R2= 4- or 6-methylpyridin-2-yl, SEM protection of intermediate 43 gave 46, which 
underwent Stille coupling with pyridinyl stannanes to afford 45b or 45c (Method C). Where R2 = 
2-methylpyridin-4-yl, Suzuki coupling of 46 with a boronic acid gave 45d (Method D). 
Intermediates 45a±d underwent Buchwald-Hartwig amination with a range of 4-substituted 1-
Me-1H-pyrazol-3-amines to give intermediates of type 47a±j, which underwent deprotection to 
give 25±34. 
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Scheme 3. Synthesis of compounds 23±34.a 
aReagents and conditions: (a) MeSO2Cl, DMF, 80 °C; (b) 1-Me-1H-pyrazol-3-amine, (tert-
Bu)ONa, Pd2(dba)3, Xantphos, DMF, 140 °C; (c) R
2B(OH)2, KF, [(tert-Bu)3P]2Pd(0), 1,4-
dioxane, water, 120 °C; (d) NaI, AcCl, MeCN, 80 °C; (e) R2B(OH)2, KF, [(tert-Bu)3P]2Pd(0), 
1,4-dioxane, H2O, 80 °C; (f) NaH, DMF, 0 °C; SEMCl, rt; (g) (n-Bu)3SnR
2, LiCl, CuI, 
Pd(PPh3)4, 1,4-dioxane, 90 °C; (h) R
2B(OH)2, Pd(PPh3)4, Cs2CO3, 1,4-dioxane, H2O, 100 °C; (i) 
1-Me-4-R1-1H-pyrazol-3-amine, (tert-Bu)ONa, Pd2(dba)3, Xantphos, PhMe, 90 °C; (j) TBAF, 
Et3N, THF, 70 °C. 
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CONCLUSIONS 
A surrogate of the ATP binding site of the LRRK2 G2019S kinase domain derived from a 10-
point mutant of checkpoint kinase 1 (CHK1 10-pt. mut.) was designed, expressed in insect cells 
infected with baculovirus and then purified and crystallized. Comparison of the binding affinity 
of 41 LRRK2 inhibitors with the mutant protein and their LRRK2 G2019S activity showed a 
moderate correlation between the two variables. X-ray crystal structures of the surrogate with 
known LRRK2 inhibitors rationalized their potency and selectivity, and its effectiveness was 
further demonstrated in the structure-guided optimization of a series of fragment-derived 
arylpyrrolo[2,3-b]-pyridines, leading to the discovery of selective LRRK2 inhibitors 22 and 23. 
In LRRK2-pSer935 HEK293 cell-based assays, the IC50 for compound 22 on LRRK2 WT, the 
overactive variant G2019S and the A2016T mutant was 24 nM, 40 nM and 471 nM, respectively. 
This confirmed that 22 is an inhibitor of LRRK2 WT and G2019S that engages Ala2016 in 
LRRK2, equivalent to Ala147 in the surrogate crystal structure. 
Compound 22 was shown to be potent, selective, orally available and brain-penetrant in wild-
type mice, and confirmation of target engagement was demonstrated with LRRK2-pSer935 IC50 
values for 22 in mouse brain and kidney being 1.3 nM and 5 nM, respectively. Compound 23 and 
analogues had increased potency and selectivity for LRRK2, but had a pharmacokinetic profile 
unsuited to further progression as CNS drug candidates. Further work demonstrating the utility 
of the CHK1 10-pt. mut. crystallographic surrogate of the LRRK2 kinase domain in the 
optimization of other chemical series of inhibitors DVSRWHQWLDOWUHDWPHQWVIRU3DUNLQVRQ¶VGLVHDVH 
will be published in due course. 
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EXPERIMENTAL SECTION 
Expression and purification of CHK1 8, 10 and 12-point mutants. A clone representing the 
constitutively active CHK1 10-point mutant (N59L, V68I, L84M, Y86L, C87A, E91S, E134H, 
S147A, F149Y, G150S) was ordered from DNA2.0 Inc. (www.dna20.com), codon optimized for 
expression in baculovirus. 
Bacmid generation using the pFastBac-1 vector was adopted as a cloning strategy with protein 
expression in Spodoptera frugiperda (Sf21) cells infected at 1e6/ml using a viral MOI = 3 and 
incubated at 27 °C, 120 rpm for 48 h. 
The resulting cell pellet was re-suspended in lysis buffer (25 mM Tris-HCl pH 8.0, 0.5M 
NaCl, 20 mM imidazole, Roche EDTA free protease inhibitor cocktail, 4 mg/L DNase) and 
dounce homogenized using 20 strokes on ice. The homogenate was then centrifuged at 18,000 
rpm for 90 min, 4 °C. 
The clarified supernatant was loaded onto a 5 ml GE Healthcare chelating column charged 
with Ni2+ and pre-equilibrated in lysis buffer. The protein load was applied at 1 ml/min and the 
column then washed back to baseline with lysis buffer. The column was then eluted (lysis buffer 
pH 8.0 + 500 mM imidazole) at 2 ml/min over 20 CV with a linear gradient to 100% elution 
buffer. Fractions of interest were analyzed using SDS-PAGE and those containing the CHK1 10- 
pt. mutant protein were pooled and concentrated using Pierce 9K MWCO spin concentrators at 4 
°C to achieve a size exclusion column load volume of <5% of the bed volume. 
The concentrated pool was then applied at 1 ml/min onto a GE Healthcare Hiload 16/60 
Superdex 75 pg size exclusion chromatography (SEC) column pre-equilibrated in SEC buffer (25 
mM Tris-HCl pH 8.0, 0.5M NaCl, 5% glycerol, 5 mM DTT) and eluted with SEC buffer at 1 
ml/min over 1.2 CV, collecting 0.5 ml fractions. 
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Samples of interest were analyzed by SDS-PAGE and the protein pool was concentrated using 
Pierce 9K MWCO spin concentrators at 4 °C. 
The final protein yield was 0.5 mg/L culture volume at 1.9 mg/ml (58 µM), 95% purity. This 
was then snap frozen in a dry ice-methanol bath, prior to being stored at ±80 °C. 
The constitutively active 12 point mutant (A19S, Y20F, N59L, V68I, L84M, Y86L, C87A, 
E91S, E134H, S147A, F149Y, G150S) was also ordered from DNA2.0, codon optimized for 
expression in baculovirus. The 8 point mutant (N59L, V68I, L84M, Y86L, C87A, E91S, E134H, 
S147A) was generated retrospectively, with DNA being generated using site directed 
mutagenesis to back mutate two of the mutations in the 10 point mutant.  Similar methodologies 
for gene cloning, protein expression and purification were used for each of the mutants produced. 
 
CHK1 8, 10 and 12-point mutant crystallization. The CHK1 10-point mutant protein was 
thawed and concentrated to 19 mg/ml. Crystals were grown using the sitting drop vapor diffusion 
method at 20 °C. The protein was mixed with an equal volume of reservoir solution containing 
7% (w/v) PEG 8000; 0.1M MES pH 6.5; 20% (v/v) ethylene glycol. Crystals appeared overnight. 
Individual crystals were then harvested and transferred to a drop containing reservoir solution 
plus ligand at a final concentration of 2 mM. This was incubated at 20 °C overnight. 
Soaked crystals were then briefly equilibrated in a cryoprotectant buffer containing reservoir 
solution plus 20% (v/v) glycerol and then flash frozen in liquid nitrogen. 
Other mutants were crystallized and soaked in ligand solutions using an identical method. 
Structures of complexes of CHK1 10 and 8-point mutants with 3b were obtained by co-
crystallization, where protein was mixed with compound (in molar ratio 1:4) prior to 
crystallization. 
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CHK1 8, 10 and 12-point mutant X-ray structure determination and refinement. 
Diffraction data were indexed and integrated using XDS79 or SAINT80 and SADABS80 (CHK1 
10-point mutant complex with 1), scaled and truncated using XSCALE79 or SCALA from the 
CCP4 suite of programs.81 The structures were solved by molecular replacement with MolRep,82 
with the 1NVR66 structure used as a starting model. All structures were refined using 
REFMAC,83 and model building was done with Coot.84 Topology files for the compounds were 
created by PRODRG85 or AceDRG.86 
 
LRRK2 WT and G2019S kinase activity assays. LRRK2 kinase activity was measured using 
a LanthaScreen kinase activity assay available from Invitrogen (ThermoFisher Scientific). GST-
tagged truncated LRRK2 kinases were also obtained from Invitrogen (ThermoFisher Scientific), 
and comprised of residues 970 to 2527 of the full length human LRRK2 WT kinase (catalogue 
no. PV4874) or a similar sequence with the G2019S mutation (catalogue no. PV4882). The 
NLQDVH UHDFWLRQV ZHUH SHUIRUPHG LQ D  ȝ/ YROXPH LQ  well plates. The kinase reaction 
buffer consisted of 50 mM Tris pH 8.5, 0.01% polyoxyethylene (23) lauryl ether (BRIJ-35), 10 
mM MgCl2, 1 mM ethylene glycol-ELVȕ-aminoethyl ether)-111ƍ1ƍ-tetraacetic acid (EGTA), 
and 2 mM DL-dithiothreitol (DTT). 
In the assay, test compound (typically at 0 to 30 µM) was added to 1.3 mM ATP and 0.4 µM 
fluorescein-LRRKtide and then the kinase reaction was initiated by addition of either 1 nM 
LRRK2 WT or 250 pM LRRK2 G2019S kinase. The reaction mixture (20 µl total volume) was 
incubated for 2 hours at 30 °C before the reaction was terminated by addition of 10 mM EDTA 
and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 40 µl). The mixture 
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was further incubated for 30 min at rt. TR-FRET was measured by excitation of the terbium-
donor with 340 nm light and subsequent measurement (delay time 100 µs) of terbium and 
fluorescein emission at 495 nm and 520 nm respectively; over a time window of 1000 µs. TR-
FRET measurements were performed on a Biomek Synergy Neo plate reader. The TR-FRET 
signal was calculated as the emission ratio at 520 nm over 495 nm. The TR-FRET ratio readout 
for test compounds was normalized to 0% inhibition, corresponding to TR-FRET ratio measured 
in control wells with no inhibition of the kinase activity and 100% inhibition, corresponding to 
TR-FRET ratio measured in control wells with 1 µM staurosporine. Test compound potency 
(IC50) was estimated by nonlinear regression using the sigmoidal dose-response (variable slope) 
using Xlfit 4 (IDBS, Guildford, Surrey, UK, model 205). y = (A+((B-A)/(1+((C/x)^D)))), where 
y is the normalized TR-FRET ratio measurement for a given concentration of test compound, x is 
the concentration of test compound, A is the estimated efficacy (% inhibition) at infinite 
compound dilution, and B is the maximal efficacy (% inhibition). C is the IC50 value and D is the 
Hill slope coefficient. IC50 estimates were obtained from a minimum of 2 independent 
experiments and the logarithmic average was calculated. 
Ki values were calculated as follows. Ki = [I]50/ ([L]50/ KD + [P]0/ KD + 1), where [I]50 denotes 
the concentration of the free inhibitor at 50% inhibition, [L]50 is the concentration of the free 
ligand (ATP) at 50% inhibition, [P]0 is the concentration of the free protein at 0% inhibition, and 
KD is the dissociation constant of the protein-ligand complex (ATP Km for LRRK2 G2019S = 96 
µM, ATP Km for LRRK2 WT = 32 µM). 
Ligand efficiency (LE) is defined as the free energy change (ǻG) associated with ligand 
binding per heavy atom, i.e. LE = -ǻG/ HAC = RTlnKi/ HAC, where R = 0.001987 (gas constant 
in kcal/ mol/ K), T = 300 (temp in K) and HAC = heavy atom count. 
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LRRK2 pSer935 and pSer1292 kinase inhibition in LRRK2 WT, G2019S and A2016T 
expressing HEK293 cells. A cell-based quantitative immunocytochemistry LRRK2 mechanistic 
kinase inhibition assay based on LRRK2-Ser935 phosphorylation as the primary read-out was 
developed using the LI-COR Odyssey near infra-red technology, also denoted as In-Cell Western 
(ICW).  The assay was performed in 96-well microplate format as previously described.70 
Additionally, the assay was performed in 384-well microplate format for LRRK2 WT and 
G2019S expressed in HEK293 cells. For the 384-well format assay, cells were transduced using 
BacMam technology (ThermoFisher Scientific). HEK293 cells were seeded in black, clear 
bottom 384-well cell-treated and poly-L-lysine-coated plates (Corning costar 3683) at a density 
of 20.000 cells/ well in 25 µl medium with 5% (v/v) BacMam LRRK2 WT or G2019S. The cells 
were incubated for 48 h before the assay was performed as previously described.70 A LRRK2-
Ser1292 phosphorylation assay was established for human LRRK2 G2019S, expressed by 
BacMam-transduced HEK293 cells grown in 384-well microplates as described for the LRRK2-
pSer935 assay above. Phosphorylation of human LRRK2 Ser1292 was detected using rabbit anti-
LRRK2-pSer1292 antibody diluted 1:800 (Epitomics).  
 
Dosing of animals for in vivo studies. All animal experiments were carried out in in 
accordance with Danish law regulating experiments on animals, in compliance with EC directive 
2010/63/EU, and the NIH guidelines on animal welfare.  The protocol used for dosing of mice 
was approved by the institutional animal ethics committee. Compound 22 was administered by 
po dosing to 6±8 week old male C57BL/6 mice (Taconic Europe A/S) using 2-hydroxypropyl-ȕ-
cyclodextrin (25% w/v) as vehicle. A compound dosing range of 0.3±24 mg/kg was used and, 
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following 1 h of compound administration, brain hemispheres were snap frozen at -80 °C using 
dry ice. One brain hemisphere to be analyzed for LRRK2-pSer935 levels using either Western 
blotting or the LRRK2-pSer935 MSD immunoassay was homogenized (10% w/v) in a standard 
tissue homogenization buffer (ThermoFisher, cat. no. FNN0071). The other brain hemisphere 
was used to determine exposure of the compound. The experiment was performed three times (n 
= 3 male mice per treatment group per experiment; total n = 9 male mice per treatment group). 
 
SDS-PAGE and Western blot-based determination of in vivo LRRK2-pSer935 inhibition. 
Brain and kidney samples were homogenized using Precellys lysing kit 0.5 ml (CK14 0.5 ml) in 
a cell lysis buffer (Sigma: C2978) with added protease (Roche: 11 697 498 011) and phosphatase 
inhibitors (Roche: 04 906 837 001). Total protein concentration was measured using a 
bicinchoninic acid (BCA) assay (ThermoFisher Pierce BCA protein assay kit, cat. no. 23225). 
Protein lysates were subjected to SDS-PAGE on a 3±8% Tris-Acetate gel (ThermoFisher 
NuPAGETM Tris-Acetate Mini Gels, cat. no. EA0375PK2) and transferred onto Immobilon-FL 
PVDF membranes (Merck Millipore, Billerica, MA, USA). After 1 h in blocking buffer, 
membranes were incubated overnight at 4 °C with primary antibodies diluted in blocking buffer: 
mouse monoclonal [N241A/34] anti-LRRK2 antibody (1:2000; NeuroMab, Davis, CA, USA) 
and rabbit monoclonal [UDD2 10(12)] anti-pS935-LRRK2 antibody (1:1000; RabMAb, Abcam, 
Cambridge, UK). Incubation with secondary antibodies was carried out for 1 h at rt: Anti-rabbit 
IgG F(c) (GOAT) antibody IRDye 800CW Conjugated (1:10,000; Rockland Immunochemicals 
Inc., Gilbertsville, USA) and anti-mouse Alexa Fluor 680 Goat anti-mouse IgM (1:20,000; 
ThermoFisher, UK). Protein visualization was detected using the LI-COR Odyssey CLx (LI-
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COR, Nebraska, USA) and total LRRK2 and pSer935 band intensities were quantified using the 
LI-COR Odyssey software (Image Studio version 3.1.4). 
 
In vivo LRRK2-pSer935 MSD assay for IC50 determination of LRRK2 inhibitors. 
Standard Meso Scale Diagnostics (MSD) Multi-array 96-well plates (Cat no: L15XA-3, MSD, 
Gaithersburg, Md, USA) were first coated with LRRK2 antibody (LRRK2-N241A/34, 
NeuroMab) at a concentration of 0.5 µg/ mL in 30 µL Tris-Base Saline (TBS). The plate was 
incubated over night at 4 °C without shaking. The plate was hereafter blocked by adding 150 µL 
5% Blocker A (from MSD) and incubated at an orbital shaker (700 rpm) for 1.5 h at rt, followed 
by washing three times with 150 µL TBS including 0.05% Tween-20. Brain protein 
homogenates was diluted in TBS to a final concentration of 6.4 µg/ µl, and a volume of 25 µL 
(160 µg total protein) was added to each well in the MSD plate. Each individual protein lysate 
was added in duplicate for either pSer935-LRRK2 or total-LRRK2 measurement on either half 
of the plate. In one half of the plate, 25 µL (0.5 µg/ml) of the pSer935-LRRK2 antibody 
(Epitomics 5099-1) diluted in TBS including 0.05% Tween-20 and 1% Blocker A was added 
while 25 µL (0.5 µg/ml) of the LRRK2 antibody (MJFF3, Abcam) diluted in TBS including 
0.05% Tween-20 and 1% Blocker A was added to the other half of the plate. The MJFF3 LRRK2 
antibody and Epitomics pS935-LRRK2 antibody recognizes a different epitope compared to the 
LRRK2 antibody used in the coating thus allowing their binding and detection of the LRKK2 
protein. The plates were incubated for one hour at room temperature with shaking at 700 rpm. 
The plate was hereafter washed three times with 150 µl per well of TBS including 0.05% Tween-
20. The secondary anti Rabbit antibody, MSD SULFO-TAG conjugated, was added to the plate 
(25 µL/ well, 1 µg/ mL) and incubated at an orbital shaker (700 rpm) for 1 h at rt, followed by 
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three times washing with TBS including 0.05% Tween-20. After addition of 150 µL 2 × Read 
buffer (MSD) the plate was measured in the MSD SECTOR S 600. The raw data was analyzed 
using the default setting of the Discovery Workbench 4.0 software (MSD). For each sample, the 
signal derived from the pSer935-LRRK2 antibody was first normalized to the signal derived 
from the total-LRRK2 antibody and then expressed in percent of pSer935-LRRK2 of vehicle 
treated samples. IC50 values were determined by non-linear regression analysis using a sigmoidal 
variable slope curve fitting using the XLfit Excel add-in. 
Chemistry. General Methods. All solvents and reagents were used as obtained from 
commercial vendors. 1H NMR spectra were collected on Bruker spectrometers and chemical 
shifts are reported in ppm relative to the residual solvent peak. All tested compounds were 
determined to be >95% pure on HPLC chromatograms obtained on an Agilent 1290 Infinity II 
series instrument (see supplementary information for LC-MS method details). Purity was 
calculated as a percentage of total area at 254 nm. The mass spectra were obtained using the 
same instrument connected to an Agilent TOF 6230 single quadrupole with a ESI source. All 
active compounds were analyzed for and found to be free of pan assay interference compounds 
(PAINS).87 
 
6-Amino-4-(3-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (22) 
Step 1. Sodium hydride (15.12 g, 0.63 mol) was added to a solution of 4-chloro-1H-
pyrrolo[2,3-b]pyridine-3-carbonitrile (11) (38.0 g, 0.21 mol) in DMF (750 mL) at 0 °C. After 10 
min, 2-(trimethylsilyl)ethoxymethyl chloride (42.8 g, 0.25 mol) was added dropwise at 0 °C. 
After completion of addition, the reaction mixture was slowly warmed to rt. After 6 h, the 
reaction mixture was poured into ice-cold water and the resulting precipitate was filtered and 
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dried in vacuo. The material was subjected to silica-gel (100-200 mesh) column chromatography 
[EtOAc-petroleum ether 40-60 (5±10%) as eluent]. The eluted material, obtained as a white solid 
(48.6 g, 74%), was identified as 4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-
b]pyridine-3-carbonitrile 37; LC-MS (Method C) (m/z) 308 [M + H]+; tR = 2.78 min. 1H NMR 
(CDCl30+]į 8.33 (1 H, d, J 5.6 Hz), 7.92 (1 H, s), 7.27 (1 H, d, J 5.2 Hz), 5.69 (2 H, s), 
3.57 (2 H, t, J 8.4 Hz), 0.92 (2 H, t, J 8.4 Hz), -0.04 (9 H, s). 
Step 2. Cesium carbonate (151 g, 0.47 mol) was added to a solution of 37 (48.0 g, 0.16 mol) 
and 3-phenylboronic acid (25.4 g, 0.19 mol) in 1,4-dioxane (1000 mL) and water (500 mL) at rt. 
The reaction mixture was degassed with argon for 30 min and then 
tetrakis(triphenylphosphine)palladium(0) (8.6 g, 0.0075 mol) was added. The reaction mixture 
was heated at 100 °C, with stirring. After 4 h, the reaction mixture was cooled to rt, diluted with 
ethyl acetate (2000 mL) and washed with water (1000 mL). The organic phase was washed with 
brine (1000 mL), dried (Na2SO4) and evaporated. The material was subjected to silica-gel (100-
200 mesh) column chromatography [EtOAc-hexanes (5±10%) as eluent]. The eluted material, 
obtained as a yellow solid (39.2 g, 69%), was identified as 4-(3-methylphenyl)-1-{[2-
(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 38; LC-MS (Method F) 
(m/z) 364 [M + H]+; tR = 1.47 min. 1H NMR (CDCl30+]į 8.47 (1 H, d, J 4.8 Hz), 7.94 
(1 H, s), 7.45±7.40 (3 H, m), 7.31 (1 H, d, J 6.8 Hz), 7.25 (1 H,s), 5.74 (2 H, s), 3.61 (2 H, t, J 
8.4 Hz), 2.47 (3 H, s), 0.94 (2 H, t, J 8.4 Hz), -0.04 (9 H, s). 
Step 3. Triethylamine (59.8 mL, 0.43 mol) and TBAF (1M in THF, 429 mL, 0.43 mol) were 
added to a solution of 38 (39.0 g, 0.11 mol) in THF (200 mL) at rt. The reaction mixture was 
heated to 65 °C. After 16 h, the reaction was cooled to rt and evaporated. The residue was diluted 
with water (1000 mL) and the resulting precipitate was filtered and dried to a white solid (21.0 g, 
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84%), identified as 4-(3-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 18, containing 
traces of TBAF; LC-MS (Method E) (m/z) 234 [M + H]+; tR = 3.29 min. 1H NMR (d6-DMSO, 
40+]į 8.52 (1 H, d, J 2.0 Hz), 8.44 (1 H, d, J 4.8 Hz), 7.45±7.41 (3 H, m), 7.32±7.31 (1 H, 
m), 7.26 (1 H, d, J 4.8 Hz), 2.40 (3 H, s).  
Step 4. m-CPBA (77%, 31.0 g, 0.18 mol) was added to a solution of 18 (21.0 g, 0.090 mol) in 
DCM (300 mL) at 0 °C. The reaction mixture was slowly warmed to rt. After 16 h, 
methanesulfonic acid (9.25 mL, 0.135 mol) was added, and the reaction mixture stirred at rt for 
15 min. Diethyl ether (1 L) was added, and the resulting precipitate was then filtered and the 
residue dried to a white solid (23.69 g, 76%), identified as 3-cyano-4-(3-methylphenyl)-1H-
pyrrolo[2,3-b]pyridin-7-ium-7-olate methylsulfonate salt 39; LC-MS (Method C) (m/z) 250 [M + 
H]+; tR = 1.76 min. 1H NMR (d6-DMSO0+]į 8.49 (1 H, s), 8.37 (1 H, d, J 6.4 Hz), 
7.44±7.40 (3 H, m), 7.31±7.29 (1 H, m), 7.26 (1 H, d, J 6.4 Hz), 2.39 (3 H, s), 2.32 (3 H, s).  
Step 5. Methanesulfonyl chloride (23.15 g, 0.205 mol) was added to a solution of 39 (23.6 g, 
0.068 mol) in DMF (500 mL) at rt. The reaction mixture was heated to 100 °C. After 2 h, the 
reaction mixture was cooled to rt, and poured onto ice-cold water (1000 mL). The resulting 
precipitate was filtered, and the residue dried to a white solid (17.2 g, 94%), identified as 6-
chloro-4-(3-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 40; LC-MS (Method C) 
(m/z) 268 [M + H]+; tR = 2.39 min. 1H NMR (CDCl30+]į 10.74 (1 H, s), 7.94 (1 H, d, J 
3.2 Hz), 7.45±7.40 (3 H, m), 7.35±7.33 (1 H, d, J 7.6 Hz), 7.30 (1 H, s), 2.48 (3 H, s).  
Step 6. A mixture of 40 (20.0 g, 74.90 mmol) and LHMDS (1.0 M in THF, 300 mL, 300 
mmol) in THF (400 mL) was degassed with argon for 10 min. 2-Dicyclohexylphosphino-ƍƍƍ-
triisopropylbiphenyl (X-Phos, 3.56 g, 7.49 mmol) and tris(dibenzylideneacetone)dipalladium(0) 
(6.85 g, 7.49 mmol) were added and allowed to stir at 65 °C. After 16 h, the reaction mixture 
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was cooled to rt, 5N hydrochloric acid (300 mL) was added, and the reaction mixture stirred for 
15 min. The mixture was then basified with sodium carbonate solution, extracted with ethyl 
acetate (2 × 500 mL) and the combined extracts dried (Na2SO4) and evaporated. The reside was 
subjected to silica-gel (100-200 mesh) column chromatography [ethyl acetate-petroleum ether 
40-60 (20±30%)]. The eluted material was evaporated to a brown solid (14.2 g), which was 
further washed with diethyl ether (250 mL). The resulting brown solid (13.4 g, 72%) was 
identified as 22; LC-MS (Method A) (m/z) 249 [M + H]+; tR = 0.88 min. 1H NMR (d6-DMSO, 
0+]į 12.03 (1 H, s), 7.91 (1 H, d, J 2.8 Hz), 7.39±7.25 (4 H, m), 6.38 (1 H, s), 6.04 (1 H, 
s), 2.38 (3 H, s). 
 
4-(3-Methylphenyl)-6-[(1-methylpyrazol-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile (23). Step 1. 11 (3.00 g, 16.89 mmol) was suspended in chloroform (60 mL) and the 
reaction mixture cooled to 0 °C. m-CPBA (10.3 g, 59.12 mmol) was then added portion-wise 
over 10 min and the reaction mixture was then stirred at rt for 16 h. Methanesulfonic acid (1.64 
mL, 21.18 mmol) was then added drop-wise over 1 min. The reaction mixture was then diluted 
with diethyl ether (60 mL), cooled (ice-water bath) and then stirred for 30 min. The resulting 
precipitate was filtered, and the residue was washed with diethyl ether (3 × 20 mL). The resulting 
solid was dried in vacuo (60 °C) for 2 h to give 5.23 g (18.03 mmol, quantitative) of a beige 
solid, identified as 4-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile-7-oxide methanesulfonic 
acid salt 35; LC-MS (Method B) (m/z) 194 [M + H]+; tR = 1.37 min. 1H NMR (DMSO-d6, 400 
0+]į+V+GJ 6.7 Hz), 7.42 (1 H, d, J 6.7 Hz). 
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Step 2. 35 (5.37 g, 18.53 mmol) was suspended in DMF (50 mL). Methanesulfonyl chloride 
(10.87 g, 95 mmol) was then added, and the reaction mixture was then heated to 80 °C for 10 
min, resulting in a pale-brown solution. The reaction mixture was then cooled and evaporated 
under reduced pressure. The resulting yellow gum was triturated with DCM. The precipitate was 
filtered and then dried to afford a light yellow powder (2.72 g, 8.52 mmol, 46%), identified as 
4,6-dichloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 41. LC-MS (Method B) (m/z) 210 [M - H]-
; tR = 2.27 min. 1H NMR (DMSO-d60+]į+V+GJ 3.0 Hz), 7.64 (1 
H, s). 
Step 3. 41 (0.376 g, 1.77 mmol), 1-methyl-1H-pyrazol-3-amine (0.189 g, 1.95 mmol), sodium 
tert-butoxide (0.852 g, 8.87 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.081 g, 0.090 
mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos, 0.113 g, 0.20 mmol) 
were added to a microwave vial, followed by dry DMF (18 mL). The reaction mixture was 
flushed with N2 for ~10 min, and then heated to 140 °C with microwaves for 1 h. The reaction 
mixture was filtered through Celite, and washed with ethyl acetate. The resulting precipitate was 
filtered and the residue dried and obtained as a yellow solid (0.242 g, 0.44 mmol, 50%) identified 
as 4-chloro-6-[(1-methyl-1H-pyrazol-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (42). 
LC-MS (Method B) (m/z) 273 [M + H]+; tR = 2.11 min.  1H NMR (DMSO-d60+]į
(1 H, s), 8.48 (1 H, s, br), 8.12 (1 H, s), 7.57 (1 H, d, J 2.2 Hz), 7.15 (1 H, s), 6.53 (1 H, d, J 2.3 
Hz), 3.76 (3 H, s). 
Step 4. 42 (0.234 g, 0.86 mmol), 3-methylphenylboronic acid (0.233 g, 1.72 mmol), potassium 
fluoride (0.150 g, 2.57 mmol), bis(tri-tert-butylphosphine)palladium(0) (0.005 g, 0.010 mmol) 
were suspended in 1,4-dioxane (15 mL) and water (2.5 mL) and stirred under a stream of 
nitrogen. The reaction mixture was then heated with microwaves at 120 °C for 60 min in a sealed 
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process vial. After cooling to room temperature, the reaction mixture was diluted with ethyl 
acetate and washed with brine. The organic phase was dried (MgSO4) and concentrated in vacuo. 
The residue was subjected to silica-gel flash column chromatography [ethyl acetate-DCM (2:1) 
as eluent]. The eluted material, obtained as a white solid (0.068 g) underwent further purification 
by preparative HPLC to afford a white solid (0.047 g, 17%), identified as 23; LC-MS (m/z) 
(Method A) 329 [M + H]+; tR = 0.94 min. 1H NMR (DMSO-d60+]į+VEU
9.44 (1 H, s), 8.05±8.04 (1 H, d), 7.55±7.54 (1 H, d), 7.42±7.38 (2 H, m), 7.35±7.32 (1 H, m), 
7.30±7.27 (1 H, m), 6.93 (1 H, s), 6.65±6.64 (1 H, d), 3.74 (3 H, s), 2.39 (3 H, s). 
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ABBREVIATIONS USED 
CHK1 10-pt. mut., 10-point mutant of checkpoint kinase 1; CL, clearance; ICW, In-Cell 
Western; LRRK2, leucine-rich repeat kinase 2; MDCK, Madin-Darby canine kidney; MLK1, 
mixed-lineage kinase; MDR1, Multi-Drug Resistance Gene; PBMC, peripheral blood 
mononuclear cell; SEM, 2-trimethylsilylethoxymethyl  
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